178 related articles for article (PubMed ID: 22836146)
1. Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.
Tabbal SD; Tian L; Karimi M; Brown CA; Loftin SK; Perlmutter JS
Exp Neurol; 2012 Oct; 237(2):355-62. PubMed ID: 22836146
[TBL] [Abstract][Full Text] [Related]
2. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
Tian L; Karimi M; Brown CA; Loftin SK; Perlmutter JS
Brain Res; 2014 Jul; 1571():49-60. PubMed ID: 24845719
[TBL] [Abstract][Full Text] [Related]
3. Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques.
Shimony JS; Rutlin J; Karimi M; Tian L; Snyder AZ; Loftin SK; Norris SA; Perlmutter JS
PLoS One; 2018; 13(9):e0202201. PubMed ID: 30183721
[TBL] [Abstract][Full Text] [Related]
4. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman AR; Bioulac B; Brotchie JM; Gross CE
J Neurosci; 2001 Sep; 21(17):6853-61. PubMed ID: 11517273
[TBL] [Abstract][Full Text] [Related]
6. Recruitment of calbindin into nigral dopamine neurons protects against MPTP-Induced parkinsonism.
Inoue KI; Miyachi S; Nishi K; Okado H; Nagai Y; Minamimoto T; Nambu A; Takada M
Mov Disord; 2019 Feb; 34(2):200-209. PubMed ID: 30161282
[TBL] [Abstract][Full Text] [Related]
7. Validation of nigrostriatal positron emission tomography measures: critical limits.
Karimi M; Tian L; Brown CA; Flores HP; Loftin SK; Videen TO; Moerlein SM; Perlmutter JS
Ann Neurol; 2013 Mar; 73(3):390-6. PubMed ID: 23423933
[TBL] [Abstract][Full Text] [Related]
8. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
9. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
10. Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.
Dugan LL; Tian L; Quick KL; Hardt JI; Karimi M; Brown C; Loftin S; Flores H; Moerlein SM; Polich J; Tabbal SD; Mink JW; Perlmutter JS
Ann Neurol; 2014 Sep; 76(3):393-402. PubMed ID: 25043598
[TBL] [Abstract][Full Text] [Related]
11. Transient dystonia correlates with parkinsonism after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in nonhuman primates.
Norris SA; Tian L; Williams EL; Perlmutter JS
Dystonia; 2023; 2():. PubMed ID: 37711667
[TBL] [Abstract][Full Text] [Related]
12. Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Yee RE; Irwin I; Milonas C; Stout DB; Huang SC; Shoghi-Jadid K; Satyamurthy N; Delanney LE; Togasaki DM; Farahani KF; Delfani K; Janson AM; Phelps ME; Langston JW; Barrio JR
Mov Disord; 2001 Sep; 16(5):838-48. PubMed ID: 11746613
[TBL] [Abstract][Full Text] [Related]
13. Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys.
Oiwa Y; Nakai K; Itakura T
Neurol Med Chir (Tokyo); 2006 Jun; 46(6):267-75; discussion 275-6. PubMed ID: 16794346
[TBL] [Abstract][Full Text] [Related]
14. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Swanson C; Emborg M
Neurol Res; 2014 Jul; 36(7):634-46. PubMed ID: 24620964
[TBL] [Abstract][Full Text] [Related]
15. Neuroimaging Analysis of the Dopamine Basis for Apathetic Behaviors in an MPTP-Lesioned Primate Model.
Tian L; Xia Y; Flores HP; Campbell MC; Moerlein SM; Perlmutter JS
PLoS One; 2015; 10(7):e0132064. PubMed ID: 26135399
[TBL] [Abstract][Full Text] [Related]
16. ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
Salvatore MF
J Neurochem; 2014 May; 129(3):548-58. PubMed ID: 24410633
[TBL] [Abstract][Full Text] [Related]
17. Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease.
Jiménez-Sánchez L; Blesa J; Del Rey NL; Monje MHG; Obeso JA; Cavada C
Neuropharmacology; 2020 Jun; 170():107806. PubMed ID: 31589886
[TBL] [Abstract][Full Text] [Related]
18. M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
Youdim MB
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S151-4. PubMed ID: 22166418
[TBL] [Abstract][Full Text] [Related]
19. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
[TBL] [Abstract][Full Text] [Related]
20. Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.
San Sebastián W; Guillén J; Manrique M; Belzunegui S; Ciordia E; Izal-Azcárate A; Garrido-Gil P; Vázquez-Claverie M; Luquin MR
Brain; 2007 May; 130(Pt 5):1306-16. PubMed ID: 17439984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
